Stock Events

Verastem 

$2.96
63
+$0.09+3.14% Today

Statistics

Day High
2.96
Day Low
2.91
52W High
15.12
52W Low
2.91
Volume
6,868
Avg. Volume
262
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.07
-0.74
-0.41
-0.08
Expected EPS
-1.03
Actual EPS
-0.98

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0LOV.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap14.79B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including those in oncology, which directly competes with Verastem's cancer-focused pipeline.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol-Myers Squibb operates in the biopharmaceutical industry, developing drugs for cancer which puts it in direct competition with Verastem's oncology segment.
AMGEN
AMGN
Mkt Cap177.72B
Amgen is a biotech company with a strong focus on cancer and oncology treatments, competing in the same space as Verastem.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences is involved in the research and development of therapeutic products in the oncology sector, making it a competitor to Verastem.
Merck &
MRK
Mkt Cap318.55B
Merck & Co., Inc. is a global healthcare company that produces cancer treatments, competing with Verastem in the oncology market.
Pfizer
PFE
Mkt Cap169.83B
Pfizer Inc. has a broad portfolio of oncology drugs, directly competing with Verastem in the cancer treatment space.
Novartis
NVS
Mkt Cap232.42B
Novartis AG engages in the research, development, and marketing of healthcare products, including oncology, which competes with Verastem's focus.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie Inc. focuses on pharmaceuticals including cancer treatments, positioning it as a competitor to Verastem.
Lilly(Eli) &
LLY
Mkt Cap814.94B
Eli Lilly and Company is a global healthcare leader that works on developing oncology drugs, making it a competitor to Verastem.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery and development of products for various disease areas including cancer, competing with Verastem.

About

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Show more...
CEO
Mr. Brian M. Stuglik BPHARM, R.Ph., RPh
Employees
48
Country
United States
ISIN
US92337C2035
WKN
000A1JTPU

Listings